 Melanoma
"Melanoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Descriptor ID |
D008545
|
| MeSH Number(s) |
C04.557.465.625.650.510 C04.557.580.625.650.510 C04.557.665.510
|
| Concept/Terms |
Melanoma- Melanoma
- Melanomas
- Malignant Melanoma
- Malignant Melanomas
- Melanoma, Malignant
- Melanomas, Malignant
|
Below are MeSH descriptors whose meaning is more general than "Melanoma".
Below are MeSH descriptors whose meaning is more specific than "Melanoma".
This graph shows the total number of publications written about "Melanoma" by people in UAMS Profiles by year, and whether "Melanoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 7 | 0 | 7 | | 2023 | 6 | 0 | 6 | | 2022 | 9 | 1 | 10 | | 2021 | 7 | 4 | 11 | | 2020 | 9 | 1 | 10 | | 2019 | 5 | 0 | 5 | | 2018 | 8 | 1 | 9 | | 2017 | 7 | 1 | 8 | | 2016 | 8 | 1 | 9 | | 2015 | 3 | 0 | 3 | | 2014 | 7 | 3 | 10 | | 2013 | 2 | 0 | 2 | | 2012 | 4 | 0 | 4 | | 2011 | 6 | 1 | 7 | | 2010 | 7 | 0 | 7 | | 2009 | 2 | 1 | 3 | | 2008 | 2 | 1 | 3 | | 2007 | 7 | 1 | 8 | | 2006 | 6 | 1 | 7 | | 2005 | 5 | 0 | 5 | | 2004 | 5 | 2 | 7 | | 2003 | 2 | 1 | 3 | | 2001 | 3 | 1 | 4 | | 2000 | 2 | 0 | 2 | | 1999 | 2 | 0 | 2 | | 1998 | 3 | 2 | 5 | | 1997 | 0 | 1 | 1 | | 1996 | 1 | 0 | 1 | | 1995 | 1 | 0 | 1 | | 1994 | 2 | 1 | 3 | | 1992 | 2 | 0 | 2 | | 1991 | 3 | 0 | 3 | | 1989 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Melanoma" by people in Profiles over the past ten years.
-
Agni M, Fiorletta Quiroga E, Stevanovic M, Venkataraman G, Shalin SC. Incidental detection of non-melanoma neoplasms in sentinel lymph node biopsy for melanoma staging: A retrospective case series. J Cutan Pathol. 2024 Dec; 51(12):1000-1007.
-
Curtis KK, Fakult NJ, Strunck JL, Aasi SZ, Ahn CS, Alam M, Bar AA, Behshad R, Bichakjian CK, Bolotin D, Boone SL, Bordeaux JS, Brewer JD, Carr DR, Carucci JA, Castillo JR, Christensen SR, Clark MA, Collins LK, Demer AM, Eisen DB, Feng H, Firoz BF, Grekin RC, Hirshburg JM, Holmes TE, Huang CC, Jennings TA, Jiang SIB, Konda S, Leitenberger JJ, Lewin JM, Maher IA, Ng E, Orengo IF, Samie FH, Saylor DK, Sharon VR, Soleymani T, Swetter SM, Tate JA, Van Beek MJ, Vidal NY, Vij A, Wysong A, Xu YG, Carroll BT, Yu WY. Establishing Consensus for Mohs Micrographic Surgical Techniques in the Treatment of Melanoma in Situ for Future Clinical Trials: A Modified Delphi Study. J Natl Compr Canc Netw. 2024 07 30; 22(8).
-
Bui CM, Vuong HG, Le MK, D'Angelo J, Mannava K, Smoller BR. Clinical implication of PRAME immunohistochemistry in differentiating melanoma in situ and dysplastic nevus in non-acral nevus-associated melanoma in situ: An institutional experience and meta-analysis. J Cutan Pathol. 2024 Oct; 51(10):783-789.
-
Kibbie JJ, Zita SM, Dellavalle RP, Dunnick CA, Armstrong CA. The number needed to biopsy for cutaneous melanoma in academic dermatology clinics. Melanoma Res. 2024 08 01; 34(4):350-354.
-
Wang L, Xiao Y, Luo Y, Master RP, Mo J, Kim MC, Liu Y, Maharjan CK, Patel UM, De U, Carelock ME, Tithi TI, Li X, Shaffer DR, Guertin KR, Zhuang H, Moser E, Smalley KSM, Lv D, Zhou D, Zheng G, Zhang W. PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. J Exp Med. 2024 Mar 04; 221(3).
-
Garg S, Morehead LC, Bird JT, Graw S, Gies A, Storey AJ, Tackett AJ, Edmondson RD, Mackintosh SG, Byrum SD, Miousse IR. Characterization of methionine dependence in melanoma cells. Mol Omics. 2024 Jan 15; 20(1):37-47.
-
Boateng ST, Roy T, Agbo ME, Mahmud MA, Banang-Mbeumi S, Chamcheu RN, Yadav RK, Bramwell M, Pham LK, Dang DD, Jackson KE, Nagalo BM, Hill RA, Efimova T, Fotie J, Chamcheu JC. Multifaceted approach toward mapping out the anticancer properties of small molecules via in?vitro evaluation on melanoma and nonmelanoma skin cancer cells, and in silico target fishing. Chem Biol Drug Des. 2024 01; 103(1):e14418.
-
Urbaniak A, Bathula C, Chauhan J, Rai P, Thammathong J, Clark C, Heflin B, De Loose A, Avaritt N, Rodriguez A, Tackett AJ, Sen S, Banerjee S. Synthesis and Anti-Melanoma Activity of Acryloyl Pyridinone Analogues. Chem Biodivers. 2023 Dec; 20(12):e202301550.
-
Morehead LC, Koss B, Fil D, Heflin B, Garg S, Wallis KF, Tackett AJ, Miousse IR. Resveratrol induces major histocompatibility complex class I antigen presentation in a STING-dependent and independent manner in melanoma. Mol Immunol. 2023 11; 163:188-195.
-
Johnson DB, Atkins MB, Hennessy C, Wise-Draper T, Heilman H, Awosika J, Bakouny Z, Labaki C, Saliby RM, Hwang C, Singh SRK, Balanchivadze N, Friese CR, Fecher LA, Yoon JJ, Hayes-Lattin B, Bilen MA, Castellano CA, Lyman GH, Tachiki L, Shah SA, Glover MJ, Flora DB, Wulff-Burchfield E, Kasi A, Abbasi SH, Farmakiotis D, Viera K, Klein EJ, Weissman LB, Jani C, Puc M, Fahey CC, Reuben DY, Mishra S, Beeghly-Fadiel A, French B, Warner JL. Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma. BMC Cancer. 2023 Mar 23; 23(1):265.
-
Ly S, Rollins B, Mohr K, Jennings T. Hair Repigmentation as a Melanoma Warning Sign. Cutis. 2023 03; 111(3):E18-E21.
-
Wang G, Zeng D, Sweren E, Miao Y, Chen R, Chen J, Wang J, Liao W, Hu Z, Kang S, Garza LA. N6-methyladenosine RNA Methylation Correlates with Immune Microenvironment and Immunotherapy Response of Melanoma. J Invest Dermatol. 2023 08; 143(8):1579-1590.e5.
-
Roy Choudhury S, Heflin B, Taylor E, Koss B, Avaritt NL, Tackett AJ. CRISPR/dCas9-KRAB-Mediated Suppression of S100b Restores p53-Mediated Apoptosis in Melanoma Cells. Cells. 2023 02 24; 12(5).
-
Zengin HB, Yildiz B, Pukhalskaya T, Smoller BR. FLI-1/Melan-A dual stain is an alternative to PRAME in differentiating metastatic melanoma from nodal nevus: A monocentric retrospective study. J Cutan Pathol. 2023 Mar; 50(3):247-258.
-
Kreher MA, Konda S, Noland MMB, Longo MI, Valdes-Rodriguez R. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors. J Am Acad Dermatol. 2023 Mar; 88(3):534-542.
-
Kreher MA, Noland MMB, Konda S, Longo MI, Valdes-Rodriguez R. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids. J Am Acad Dermatol. 2023 Mar; 88(3):521-530.
-
Poudel I, Annaji M, Wibowo FS, Arnold RD, Fasina O, Via B, Rangari V, Peresin MS, Smith F, Dhanasekaran M, Tiwari AK, Babu RJ. Hispolon Cyclodextrin Complexes and Their Inclusion in Liposomes for Enhanced Delivery in Melanoma Cell Lines. Int J Mol Sci. 2022 Nov 21; 23(22).
-
Gitin A, Valdes-Rodriguez R, Canipe A. Pigmented Polypoid Lesion in a 24-Year-Old Woman With Hematochezia. Gastroenterology. 2022 12; 163(6):e16-e17.
-
Paidi SK, Troncoso JR, Harper MG, Liu Z, Nguyen KG, Ravindranathan S, Rebello L, Lee DE, Ivers JD, Zaharoff DA, Rajaram N, Barman I. Raman spectroscopy reveals phenotype switches in breast cancer metastasis. Theranostics. 2022; 12(12):5351-5363.
-
Plotzke JM, Zoumberos NA, Hrycaj SM, Harms PW, Bresler SC, Chan MP. PRAME expression is similar in scar and desmoplastic melanoma. J Cutan Pathol. 2022 09; 49(9):829-832.
-
Walker RJB, Look Hong NJ, Moncrieff M, van Akkooi ACJ, Jost E, Nessim C, van Houdt WJ, Stahlie EHA, Seo C, Quan ML, McKinnon JG, Wright FC, Mavros MN. Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma: An International Multi-institutional Collaboration. Ann Surg Oncol. 2022 Oct; 29(11):7010-7017.
-
Jawad HJ, Yadem AC, Menyaev YA, Sarimollaoglu M, Armstrong JN, Watanabe F, Biris AS, Stumhofer JS, Nedosekin D, Suen JY, Parikh S, Zharov VP. Towards rainbow portable Cytophone with laser diodes for global disease diagnostics. Sci Rep. 2022 05 23; 12(1):8671.
-
Henry W, Nash S, Pemberton J. Conjunctival Melanoma of the Left Lower Eyelid. Cutis. 2022 05; 109(5):E25-E27.
-
Guo X, Jessel S, Qu R, Kluger Y, Chen TM, Hollander L, Safirstein R, Nelson B, Cha C, Bosenberg M, Jilaveanu LB, Rimm D, Rothlin CV, Kluger HM, Desir GV. Inhibition of renalase drives tumour rejection by promoting T cell activation. Eur J Cancer. 2022 04; 165:81-96.
-
Lewis GD, Guzman AK, Haque W, McLellan BN, Teh BS. Comparison of Survival Outcomes With/Without Adjuvant Radiation Therapy in Desmoplastic Melanoma. Dermatol Surg. 2021 10 01; 47(10):1333-1336.
-
Wolfe AR, Chablani P, Siedow MR, Miller ED, Walston S, Kendra KL, Wuthrick E, Williams TM. BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma. Radiat Oncol. 2021 Sep 18; 16(1):181.
-
Zhang M, Acklin S, Gillenwater J, Du W, Patra M, Yu H, Xu B, Yu J, Xia F. SIRT2 promotes murine melanoma progression through natural killer cell inhibition. Sci Rep. 2021 06 21; 11(1):12988.
-
Palliyage GH, Hussein N, Mimlitz M, Weeder C, Alnasser MHA, Singh S, Ekpenyong A, Tiwari AK, Chauhan H. Novel Curcumin-Resveratrol Solid Nanoparticles Synergistically Inhibit Proliferation of Melanoma Cells. Pharm Res. 2021 May; 38(5):851-871.
-
Tarhini AA, Kang N, Lee SJ, Hodi FS, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021 05; 9(5).
-
Fuhrman BJ, Moore SC, Byrne C, Makhoul I, Kitahara CM, Berrington de Gonz?lez A, Linet MS, Weiderpass E, Adami HO, Freedman ND, Liao LM, Matthews CE, Stolzenberg-Solomon RZ, Gaudet MM, Patel AV, Lee IM, Buring JE, Wolk A, Larsson SC, Prizment AE, Robien K, Spriggs M, Check DP, Murphy N, Gunter MJ, Van Dusen HL, Ziegler RG, Hoover RN. Association of the Age at Menarche with Site-Specific Cancer Risks in Pooled Data from Nine Cohorts. Cancer Res. 2021 04 15; 81(8):2246-2255.
-
Gradecki SE, Valdes-Rodriguez R, Wick MR, Gru AA. PRAME immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna. Histopathology. 2021 Jun; 78(7):1000-1008.
-
Parra O, Bridge JA, Busam KJ, Shalin SC, Linos K. Dermal melanocytic tumor with CRTC1-TRIM11 fusion: Report of two additional cases with review of the literature of an emerging entity. J Cutan Pathol. 2021 Jul; 48(7):915-924.
-
Wallis KF, Morehead LC, Bird JT, Byrum SD, Miousse IR. Differences in cell death in methionine versus cysteine depletion. Environ Mol Mutagen. 2021 03; 62(3):216-226.
-
Kozlova A, Bratashov D, Grishin O, Abdurashitov A, Prikhozhdenko E, Verkhovskii R, Shushunova N, Shashkov E, Zharov VP, Inozemtseva O. Dynamic blood flow phantom for in vivo liquid biopsy standardization. Sci Rep. 2021 01 13; 11(1):1185.
-
He Y, Li W, Zhang J, Yang Y, Qian Y, Zhou D. The Curcumin Analog EF24 is Highly Active Against Chemotherapy- Resistant Melanoma Cells. Curr Cancer Drug Targets. 2021; 21(7):608-618.
-
Yasin H, Yadala V, Khan NAJ, Graffeo V, Denning K, Lebowicz Y. Immunotherapy-Induced Sarcoid-Like Reaction: A Shrewd Imitator. J Investig Med High Impact Case Rep. 2021 Jan-Dec; 9:23247096211009400.
-
Kurakula M, Chen L, Tiwari AK, Srinivas NR, Dash RP, Panizzi PR, Arnold RD, Babu RJ. Recent Advances in Lipid-Based Nanovesicular Delivery Systems for Melanoma Therapy. Crit Rev Ther Drug Carrier Syst. 2021; 38(4):1-38.
-
Roy T, Boateng ST, Banang-Mbeumi S, Singh PK, Basnet P, Chamcheu RN, Ladu F, Chauvin I, Spiegelman VS, Hill RA, Kousoulas KG, Nagalo BM, Walker AL, Fotie J, Murru S, Sechi M, Chamcheu JC. Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers. Bioorg Chem. 2021 02; 107:104595.
-
Al Saqr A, Aldawsari MF, Alrbyawi H, Poudel I, Annaji M, Mulabagal V, Ramani MV, Gottumukkala S, Tiwari AK, Dhanasekaran M, Panizzi PR, Arnold RD, Babu RJ. Co-Delivery of Hispolon and Doxorubicin Liposomes Improves Efficacy Against Melanoma Cells. AAPS PharmSciTech. 2020 Nov 04; 21(8):304.
-
Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T, Bushway ME, Balogh KN, Sciuto TE, Kohler V, Turnbull SJ, Besada R, Curran RR, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting YS, Dong JZ, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary LD, Moles MA, Manson K, Greshock J, Khondker ZS, Fritsch E, Rooney MS, DeMario M, Gaynor RB, Srinivasan L. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 2020 10 15; 183(2):347-362.e24.
-
Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF, Lao C, Faller BA, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat Med. 2020 10; 26(10):1564-1568.
-
Campbell KK, Gardner JM, Hall K, Osborne A, Shalin SC. Consecutive Immunohistochemical Staining on a Single Slide is Effective in Confirming Melanocytic Derivation. Appl Immunohistochem Mol Morphol. 2020 10; 28(9):e76-e81.
-
Taylor EM, Byrum SD, Edmondson JL, Wardell CP, Griffin BG, Shalin SC, Gokden M, Makhoul I, Tackett AJ, Rodriguez A. Proteogenomic analysis of melanoma brain metastases from distinct anatomical sites identifies pathways of metastatic progression. Acta Neuropathol Commun. 2020 09 05; 8(1):157.
-
Miousse IR, Tobacyk J, Quick CM, Jamshidi-Parsian A, Skinner CM, Kore R, Melnyk SB, Kutanzi KR, Xia F, Griffin RJ, Koturbash I. Reply to Flugge: the anti-metastatic potential of methionine restriction in melanoma. Carcinogenesis. 2020 05 14; 41(3):390-391.
-
Donizy P, Wu CL, Mull J, Fujimoto M, Chlopik A, Peng Y, Shalin SC, Selim MA, Puig S, Fernandez-Figueras MT, Shea CR, Biernat W, Rys J, Marszalek A, Hoang MP. Up-Regulation of PARP1 Expression Significantly Correlated with Poor Survival in Mucosal Melanomas. Cells. 2020 05 05; 9(5).
-
Davis LE, Shalin SC, Tackett AJ. Utility of histone H3K27me3 and H4K20me as diagnostic indicators of melanoma. Melanoma Res. 2020 04; 30(2):159-165.
-
Joshi K, Atwal D, Ravilla R, Pandey Y, Yarlagadda N, Kakadia S, Makhoul I, Hutchins L, Mahmoud F. Immunotherapy Outcomes in Advanced Melanoma in Relation to Age. Perm J. 2020; 24.
-
Tarhini AA, Lee SJ, Hodi FS, Rao UNM, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. J Clin Oncol. 2020 02 20; 38(6):567-575.
-
Nagarajan P, Piao J, Ning J, Noordenbos LE, Curry JL, Torres-Cabala CA, Diwan AH, Ivan D, Aung PP, Ross MI, Royal RE, Wargo JA, Wang WL, Samdani R, Lazar AJ, Rashid A, Davies MA, Prieto VG, Gershenwald JE, Tetzlaff MT. Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Mod Pathol. 2020 03; 33(3):496-513.
-
Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019; 20(11):1366-1379.
-
Heenatigala Palliyage G, Singh S, Ashby CR, Tiwari AK, Chauhan H. Pharmaceutical Topical Delivery of Poorly Soluble Polyphenols: Potential Role in Prevention and Treatment of Melanoma. AAPS PharmSciTech. 2019 Jul 11; 20(6):250.
-
Galanzha EI, Menyaev YA, Yadem AC, Sarimollaoglu M, Juratli MA, Nedosekin DA, Foster SR, Jamshidi-Parsian A, Siegel ER, Makhoul I, Hutchins LF, Suen JY, Zharov VP. In vivo liquid biopsy using Cytophone platform for photoacoustic detection of circulating tumor cells in patients with melanoma. Sci Transl Med. 2019 06 12; 11(496).
-
Radisic A, Hundley K, Patel N, Nelson C, Mhaskar R. Assessment of impact of a skin cancer education session on cosmetology students' knowledge and preparedness to assess future clients for skin lesions. J Cosmet Dermatol. 2020 Jan; 19(1):205-210.
-
van Laar RK, Lincoln MT, van Laar BJ. A plasma microRNA biomarker of melanoma as a personalised assessment of treatment response. Melanoma Res. 2019 02; 29(1):19-22.
-
Miousse IR, Tobacyk J, Quick CM, Jamshidi-Parsian A, Skinner CM, Kore R, Melnyk SB, Kutanzi KR, Xia F, Griffin RJ, Koturbash I. Modulation of dietary methionine intake elicits potent, yet distinct, anticancer effects on primary versus metastatic tumors. Carcinogenesis. 2018 09 21; 39(9):1117-1126.
-
Bsirini C, Smoller BR. Histologic mimics of malignant melanoma. Singapore Med J. 2018 Nov; 59(11):602-607.
-
Mudambi S, Pera P, Washington D, Remenyik E, Fidrus E, Shafirstein G, Bellnier D, Paragh G. Photodynamic therapy does not induce cyclobutane pyrimidine dimers in the presence of melanin. Photodiagnosis Photodyn Ther. 2018 Jun; 22:241-244.
-
Dinehart M, Abate MS, Jennings T, Kaley JR, Shalin SC. Colliding, colonizing or combining? Four cases illustrating the unique challenges presented by melanoma arising in conjunction with basal cell carcinoma. J Cutan Pathol. 2018 Jun; 45(6):443-452.
-
Damato B, Hope-Stone L, Cooper B, Brown SL, Salmon P, Heimann H, Dunn LB. Patient-reported Outcomes and Quality of Life After Treatment of Choroidal Melanoma: A Comparison of Enucleation Versus Radiotherapy in 1596 Patients. Am J Ophthalmol. 2018 09; 193:230-251.
-
Campbell K, Kumarapeli AR, Gokden N, Cox RM, Hutchins L, Gardner JM. Metastatic melanoma with dedifferentiation and extensive rhabdomyosarcomatous heterologous component. J Cutan Pathol. 2018 May; 45(5):360-364.
-
Bagati A, Bianchi-Smiraglia A, Moparthy S, Kolesnikova K, Fink EE, Kolesnikova M, Roll MV, Jowdy P, Wolff DW, Polechetti A, Yun DH, Lipchick BC, Paul LM, Wrazen B, Moparthy K, Mudambi S, Morozevich GE, Georgieva SG, Wang J, Shafirstein G, Liu S, Kandel ES, Berman AE, Box NF, Paragh G, Nikiforov MA. FOXQ1 controls the induced differentiation of melanocytic cells. Cell Death Differ. 2018 06; 25(6):1040-1049.
-
Chesney J, Awasthi S, Curti B, Hutchins L, Linette G, Triozzi P, Tan MCB, Brown RE, Nemunaitis J, Whitman E, Windham C, Lutzky J, Downey GF, Batty N, Amatruda T. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma. Melanoma Res. 2018 02; 28(1):44-51.
-
Ross CL, Kaushik S, Valdes-Rodriguez R, Anvekar R. MicroRNAs in cutaneous melanoma: Role as diagnostic and prognostic biomarkers. J Cell Physiol. 2018 07; 233(7):5133-5141.
-
Chlopik A, Selim MA, Peng Y, Wu CL, Tell-Marti G, Paral KM, Shalin SC, Kraft S, Hsu CK, Shea CR, Puig S, Fernandez-Figueras MT, Biernat W, Rys J, Marszalek A, Hoang MP. Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas. Hum Pathol. 2018 03; 73:176-183.
-
Dias-Santagata D, Selim MA, Su Y, Peng Y, Vollmer R, Chlopik A, Tell-Marti G, Paral KM, Shalin SC, Shea CR, Puig S, Fernandez-Figueras MT, Biernat W, Rys J, Marszalek A, Hoang MP. KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas. Br J Dermatol. 2017 Nov; 177(5):1376-1384.
-
Perez MC, Orcutt ST, Zager JS. Current standards of surgical management in primary melanoma. G Ital Dermatol Venereol. 2018 Feb; 153(1):56-67.
-
Kaidar-Person O, Zagar TM, Deal A, Moschos SJ, Ewend MG, Sasaki-Adams D, Lee CB, Collichio FA, Fried D, Marks LB, Chera BS. The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy. Anticancer Drugs. 2017 07; 28(6):669-675.
-
Leon-Castillo A, Chrisinger JSA, Panse G, Samdani RT, Ingram DR, Ravi V, Prieto VG, Wang WL, Lazar AJ. Index report of cutaneous angiosarcomas with strong positivity for tyrosinase mimicking melanoma with further evaluation of melanocytic markers in a large angiosarcoma series. J Cutan Pathol. 2017 Aug; 44(8):692-697.
-
Mahmoud F, Shields B, Makhoul I, Avaritt N, Wong HK, Hutchins LF, Shalin S, Tackett AJ. Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack. Cancer Biol Ther. 2017 Jul 03; 18(7):451-469.
-
Shields BD, Mahmoud F, Taylor EM, Byrum SD, Sengupta D, Koss B, Baldini G, Ransom S, Cline K, Mackintosh SG, Edmondson RD, Shalin S, Tackett AJ. Indicators of responsiveness to immune checkpoint inhibitors. Sci Rep. 2017 04 11; 7(1):807.
-
Mahmoud F, Wilkinson JT, Gizinski A, Viswamitra S, Gokden N, Vander Schilden J. Could knee inflammatory synovitis be induced by pembrolizumab? J Oncol Pharm Pract. 2018 Jul; 24(5):389-392.
-
Garrett GL, Blanc PD, Boscardin J, Lloyd AA, Ahmed RL, Anthony T, Bibee K, Breithaupt A, Cannon J, Chen A, Cheng JY, Chiesa-Fuxench Z, Colegio OR, Curiel-Lewandrowski C, Del Guzzo CA, Disse M, Dowd M, Eilers R, Ortiz AE, Morris C, Golden SK, Graves MS, Griffin JR, Hopkins RS, Huang CC, Bae GH, Jambusaria A, Jennings TA, Jiang SI, Karia PS, Khetarpal S, Kim C, Klintmalm G, Konicke K, Koyfman SA, Lam C, Lee P, Leitenberger JJ, Loh T, Lowenstein S, Madankumar R, Moreau JF, Nijhawan RI, Ochoa S, Olasz EB, Otchere E, Otley C, Oulton J, Patel PH, Patel VA, Prabhu AV, Pugliano-Mauro M, Schmults CD, Schram S, Shih AF, Shin T, Soon S, Soriano T, Srivastava D, Stein JA, Sternhell-Blackwell K, Taylor S, Vidimos A, Wu P, Zajdel N, Zelac D, Arron ST. Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States. JAMA Dermatol. 2017 03 01; 153(3):296-303.
-
Shalin SC. A review of kinase fusions in melanocytic tumors. Lab Invest. 2017 02; 97(2):158-165.
-
Kaya S, Bayraktar M, Kockara S, Mete M, Halic T, Field HE, Wong HK. Abrupt skin lesion border cutoff measurement for malignancy detection in dermoscopy images. BMC Bioinformatics. 2016 Oct 06; 17(Suppl 13):367.
-
Firwana B, Ravilla R, Raval M, Hutchins L, Mahmoud F. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract. 2017 Dec; 23(8):620-624.
-
Williams TJ, Benavides DR, Patrice KA, Dalmau JO, de ?vila AL, Le DT, Lipson EJ, Probasco JC, Mowry EM. Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. JAMA Neurol. 2016 Aug 01; 73(8):928-33.
-
Atrash S, Makhoul I, Mizell JS, Hutchins L, Mahmoud F. Response of metastatic mucosal melanoma to immunotherapy: It can get worse before it gets better. J Oncol Pharm Pract. 2017 Apr; 23(3):215-219.
-
Erstine EM, Elwood HR, Westbrook KC, McCalmont TH, Shalin SC, Gardner JM. Desmoplastic melanoma presenting as primary alopecia neoplastica: a report of two cases. J Cutan Pathol. 2016 Oct; 43(10):872-9.
-
Yao X, Lu YC, Parker LL, Li YF, El-Gamil M, Black MA, Xu H, Feldman SA, van der Bruggen P, Rosenberg SA, Robbins PF. Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy. J Immunother. 2016 06; 39(5):191-201.
-
Hollander L, Guo X, Velazquez H, Chang J, Safirstein R, Kluger H, Cha C, Desir GV. Renalase Expression by Melanoma and Tumor-Associated Macrophages Promotes Tumor Growth through a STAT3-Mediated Mechanism. Cancer Res. 2016 07 01; 76(13):3884-94.
-
Mahmoud F, Shields B, Makhoul I, Hutchins LF, Shalin SC, Tackett AJ. Role of EZH2 histone methyltrasferase in melanoma progression and metastasis. Cancer Biol Ther. 2016 06 02; 17(6):579-91.
-
Klair JS, Girotra M, Hutchins LF, Caradine KD, Aduli F, Garcia-Saenz-de-Sicilia M. Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm. Dig Dis Sci. 2016 07; 61(7):2132-9.
-
Tran KA, Cheng MY, Mitra A, Ogawa H, Shi VY, Olney LP, Kloxin AM, Maverakis E. MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy. Drug Des Devel Ther. 2016; 10:43-52.
-
Johnston MJ, Ntambi JA, Hilliard N, Spencer HJ, Vaughn R, Owens SS, Myrick RS, Parker LD, Garner DA, Yarbrough TL. Reducing perceived pain levels during nonbreast lymphoscintigraphy. Clin Nucl Med. 2015 Dec; 40(12):945-9.
-
Shi VY, Tran K, Patel F, Leventhal J, Konia T, Fung MA, Wilken R, Garcia MS, Fitzmaurice SD, Joo J, Monjazeb AM, Burrall BA, King B, Martinez S, Christensen SD, Maverakis E. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series. J Am Acad Dermatol. 2015 Oct; 73(4):645-54.
-
Walsh SB, Varma R, Raimer D, Keane JC, Cantor A, Theos A, Northington M, Huang CC. Utility of Wood's light in margin determination of melanoma in situ after excisional biopsy. Dermatol Surg. 2015 May; 41(5):572-8.
-
Abdallah AO, Herlopian A, Ravilla R, Bansal M, Chandra-Reddy S, Mahmoud F, Ong S, Gokden M, Hutchins L. Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature. J Oncol Pharm Pract. 2016 Jun; 22(3):537-42.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|